Carlos Becerra, MD
Emerging data are changing the treatment paradigm in pancreatic cancer, offering patients new options and more personalized care, according to Carlos Becerra, MD.
State of the Science Summit™ on Gastrointestinal Malignancies, Becerra, medical oncologist, Texas Oncology, discussed sequencing strategies, immunotherapy, and practice-changing clinical trials in the field of pancreatic cancer.
OncLive: What did your presentation focus on?
: I talked a little bit about frontline chemotherapy for patients with metastatic pancreas cancer and how best to sequence the different agents that we have available to try to improve survival in these patients.
How do you approach sequencing?
Right now, we do not have a head-to-head comparison between the different agents. Therefore, in younger patients with a robust performance status there is a trend to treat them with FOLFIRINOX.
... to read the full story